Many available PARP inhibitors (PARPi) are used in clinics, but many are inducing resistance over time [41], and it has been shown that cancer cells use upregulation of PARP1 as a mechanism to become resistant to PARPi [42]. This evidence concerns the gene PARP1 and cancer.